Observational studyThe oncologist2019
Assessment of NETest Clinical Utility in a U.S. Registry-Based Study.
Observational study in The oncologist, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02270567 (A Registry for Neuroendocrine Tumors), which is not on this map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Registry for Neuroendocrine Tumors
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- Pooled it
- Clinical Value of a 51-Neuroendocrine Tumor-Specific Gene Signature (NETest 2.0) for Management of Pancreatic and Small Bowel Neuroendocrine Tumors: A Prospective Study in a Consecutive Cohort of 82 Patients Considered for Surgery.Annals of surgery open : perspectives of surgical history, education, and clinical approaches · 2026Article
- NETest2.0Cancers · 2026Article
- Clinical Validity of NETest2.0Cancers · 2026Article
- NETest® 2.0-A decade of innovation in neuroendocrine tumor diagnostics.Journal of neuroendocrinology · 2025Article
- A blood-based liquid biopsy analyzing soluble immune checkpoints and cytokines identifies distinct neuroendocrine tumors.Journal of experimental & clinical cancer research : CR · 2025Article
- Review
- Biochemical Markers for Neuroendocrine Tumors: Traditional Circulating Markers and Recent Development-A Comprehensive Review.Diagnostics (Basel, Switzerland) · 2024Review
- Gastroenteropancreatic neuroendocrine neoplasms: current development, challenges, and clinical perspectives.Military Medical Research · 2024Review
- The Molecular Biology of Midgut Neuroendocrine Neoplasms.Endocrine reviews · 2024Review
- Does gamma-glutamyltransferase correlate with liver tumor burden in neuroendocrine tumors?Endocrine · 2024Article
- The Quest for Circulating Biomarkers in Neuroendocrine Neoplasms: a Clinical Perspective.Current treatment options in oncology · 2023Review
- Dual role of autotaxin as novel biomarker and therapeutic target in pancreatic neuroendocrine neoplasms.Cancer science · 2023Article
- Correlation between clinicopathological characteristics and the clinical prognosis of patients with gastroenteropancreatic neuroendocrine tumors.Molecular and clinical oncology · 2023Article
- An Overview of Circulating Biomarkers in Neuroendocrine Neoplasms: A Clinical Guide.Diagnostics (Basel, Switzerland) · 2023Review
- Interim Analysis of a Prospective Validation of 2 Blood-Based Genomic Assessments (PPQ and NETest) to Determine the Clinical Efficacy ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Emerging Immunotherapeutic and Diagnostic Modalities in Carcinoid Tumors.Molecules (Basel, Switzerland) · 2023Review
- Circulating Neuroendocrine Tumor Biomarkers: Past, Present and Future.Journal of clinical medicine · 2022Review
- Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs).Cancers · 2022Review
- An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms.World journal of gastroenterology · 2022Review
Corrections and comments
- Commented on by
Authors and funding
9 authors at 8 institutions in 1 country.
Funding
Abstract
backgroundThe clinical relevance of molecular biomarkers in oncology management has been recognized in breast and lung cancers. We evaluated a blood-based multigene assay for management of neuroendocrine tumors (NETs) in a real-world study (U.S. registry NCT02270567). Diagnostic accuracy and relationship to clinical disease status in two cohorts (treated and watch-and-wait) were evaluated. MATERIALS AND
methodsPatients with NETs (
resultsNETest diagnostic accuracy was 96% and concordant (95%) with image-demonstrable disease. Scores were reproducible (97%) and concordant with clinical status (98%). The NETest was the only feature linked to PFS (odds ratio, 6.1;
conclusionBlood NETest is an accurate diagnostic and can be of use in monitoring disease status and facilitating management change in both watch-and-wait and treatment cohorts. IMPLICATIONS FOR PRACTICE: A circulating multigene molecular biomarker to guide neuroendocrine tumor (NET) management has been developed because current biomarkers have limited clinical utility. NETest is diagnostic (96%) and in real time defines the disease status (>95%) as stable or progressive. It is >90% effective in guiding treatment decisions in conjunction with diagnostic imaging. Monitoring was effective in watch-and-wait or treatment groups. Low levels supported no management change and reduced the need for imaging. High levels indicated the need for management intervention. Real-time liquid biopsy assessment of NETs has clinical utility and can contribute additional value to patient management strategies and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.